Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer

被引：0
|
作者：
Mohammed A Aleskandarany
Andrew R Green
Ahmed A Benhasouna
Fabricio F Barros
Keith Neal
Jorge S Reis-Filho
Ian O Ellis
Emad A Rakha
机构：
[1] University of Nottingham and Nottingham University Hospitals NHS Trust,Department of Histopathology, School of Molecular Medical Sciences, Queens Medical Centre
[2] Menoufia University,Pathology Department, Faculty of Medicine
[3] Shebin El-Kom,Occupational Health, School of Molecular Medical Sciences, Queens Medical Centre
[4] University of Nottingham and Nottingham University Hospitals NHS Trust,Breakthrough Breast Cancer Research Centre
[5] Institute of Cancer Research,undefined
来源：
Breast Cancer Research | / 14卷
关键词：
Breast Cancer; Mitotic Count; Breast Cancer Specific Survival; Luminal Tumor; Invasive Breast Cancer Case;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
    Aleskandarany, Mohammed A.
    Green, Andrew R.
    Benhasouna, Ahmed A.
    Barros, Fabricio F.
    Neal, Keith
    Reis-Filho, Jorge S.
    Ellis, Ian O.
    Rakha, Emad A.
    BREAST CANCER RESEARCH, 2012, 14 (01):
  • [2] Neoadjuvant chemotherapy in HER2-positive and triple-negative breast cancer
    Goncalves, Anthony
    BULLETIN DU CANCER, 2016, 103 (06) : S76 - S89
  • [3] PROGNOSTIC SIGNIFICANCE OF ANDROGEN RECEPTOR EXPRESSION IN HER2-POSITIVE AND TRIPLE-NEGATIVE BREAST CANCER
    Kucukzeybek, Betul Bolat
    Bayoglu, Ibrahim V.
    Kucukzeybek, Yuksel
    Yildiz, Yasar
    Oflazoglu, Utku
    Atahan, Murat K.
    Taskaynatan, Halil
    Alacacioglu, Ahmet
    Yigit, Seyran
    Tarhan, Mustafa O.
    POLISH JOURNAL OF PATHOLOGY, 2018, 69 (02) : 157 - 168
  • [4] Updates in HER2-Positive and Triple-Negative Breast Cancers
    Telli, Melinda L.
    Gradishar, William J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 605 - 609
  • [5] The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer
    Leon-Ferre, Roberto A.
    Hieken, Tina J.
    Boughey, Judy C.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (04) : 2111 - 2119
  • [6] SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
    Bartsch, Rupert
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2021, 14 (03) : 247 - 251
  • [7] Survival of triple-negative and HER2-positive breast cancer by AJCC stage.
    Caggiano, V.
    Bauer, K.
    Parise, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
    Rupert Bartsch
    memo - Magazine of European Medical Oncology, 2021, 14 : 247 - 251
  • [9] The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer
    Roberto A. Leon-Ferre
    Tina J. Hieken
    Judy C. Boughey
    Annals of Surgical Oncology, 2021, 28 : 2111 - 2119
  • [10] Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers
    Bayoglu, Ibrahim Vedat
    Kucukzeybek, Betul Bolat
    Kucukzeybek, Yuksel
    Varol, Umut
    Yildiz, Ibrahim
    Alacacioglu, Ahmet
    Akyol, Murat
    Demir, Lutfiye
    Dirican, Ahmet
    Yildiz, Yasar
    Salman, Tarik
    Tarhan, Mustafa Oktay
    BIOMEDICINE & PHARMACOTHERAPY, 2015, 70 : 190 - 195
12345